Numis Securities reiterated their buy rating on shares of Abzena (LON:ABZA) in a research note published on Wednesday morning. Numis Securities currently has a GBX 80 ($1.08) price objective on the stock.
Separately, FinnCap restated a buy rating and set a GBX 70 ($0.94) price objective on shares of Abzena in a research note on Monday, December 11th.
Shares of Abzena (LON ABZA) remained flat at $GBX 33 ($0.44) during trading hours on Wednesday. 2,346 shares of the company’s stock were exchanged, compared to its average volume of 123,688. Abzena has a 12 month low of GBX 27.73 ($0.37) and a 12 month high of GBX 66 ($0.89).
COPYRIGHT VIOLATION WARNING: “Abzena’s (ABZA) “Buy” Rating Reiterated at Numis Securities” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/12/16/abzenas-abza-buy-rating-reiterated-at-numis-securities.html.
Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.
Receive News & Ratings for Abzena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena and related companies with MarketBeat.com's FREE daily email newsletter.